Financings in Brief: Lifecore Biomedical
This article was originally published in The Gray Sheet
Lifecore Biomedical: Firm's board of directors adopts shareholder rights plan, intended to "ensure that all of the company's shareholders receive fair and equal treatment in the event of any proposal to acquire the company." Distribution of rights, which become exercisable "following the acquisition by a person or group, without the prior consent of the Lifecore Board, of 15 percent or more of the company's voting stock, or following the announcement of a tender offer or exchange offer to acquire an interest of 15 percent or more"...
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.